Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
- Study type
- Other
- Design
- Short report (research highlight) in Nature Reviews Clinical Oncology; no abstract in the PubMed record
- Sample size
- Not stated in the PubMed record
- Source
- Nat Rev Clin Oncol · 2025
In plain words
This is a short news summary in a specialist cancer journal. According to its title, adding the immunotherapy drug durvalumab to FLOT chemotherapy, which is given before and after surgery for stomach cancer, improved patients' outcomes. To find out how much benefit there is, what the side effects are and whether this treatment suits your situation, be sure to talk to your treating doctor.
Study population
The PubMed record has no abstract or information on the patient population. Details in the full text.
Endpoints
The PubMed record has no abstract and endpoints are not stated. Details in the full text.
Safety and side effects
The PubMed record has no information on adverse events. Details in the full text.
Clinical significance and place in guidelines
The available record provides only the title and is not sufficient to judge the impact on clinical practice. The status of approvals and clinical guideline recommendations on adding durvalumab to perioperative FLOT should be checked in reliable sources and the full text.
Limitations
The PubMed record lacks an abstract, and the article is a short research highlight, not the primary trial report. No numerical data (design, dose, sample size, results or adverse events) are in the record, and the full text and the primary trial paper should be consulted to complete the card.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.